Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131456 · ClinicalTrials.gov registry record · Phase 2
Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT00131456 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 123 participants.
The verdict
NCT00131456, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Venlafaxine Extended Release (Ven-XR) is effective in treating individuals with marijuana addiction and depression.
Interventions
- DRUG Placebo
- DRUG Venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2004-03 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131456
The ClinicalTrials.gov registry entry for NCT00131456 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00131456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00131456 about?
NCT00131456 is a clinical study titled "Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1". The purpose of this study is to determine if Venlafaxine Extended Release (Ven-XR) is effective in treating individuals with marijuana addiction and depression.
What is the current status of trial NCT00131456?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2004-03. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00131456?
The interventions under investigation include: Placebo (DRUG), Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00131456?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.